89bio Statistics
Total Valuation
89bio has a market cap or net worth of $777.23 million. The enterprise value is $242.24 million.
Market Cap | 777.23M |
Enterprise Value | 242.24M |
Important Dates
The last earnings date was Thursday, May 9, 2024, after market close.
Earnings Date | May 9, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
89bio has 98.38 million shares outstanding. The number of shares has increased by 80.26% in one year.
Shares Outstanding | 98.38M |
Shares Change (YoY) | +80.26% |
Shares Change (QoQ) | +18.62% |
Owned by Insiders (%) | 0.71% |
Owned by Institutions (%) | 106.87% |
Float | 69.80M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.52 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.03, with a Debt / Equity ratio of 0.05.
Current Ratio | 15.03 |
Quick Ratio | n/a |
Debt / Equity | 0.05 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -43.97 |
Financial Efficiency
Return on equity (ROE) is -34.80% and return on invested capital (ROIC) is -33.46%.
Return on Equity (ROE) | -34.80% |
Return on Assets (ROA) | -31.00% |
Return on Capital (ROIC) | -33.46% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.36M |
Employee Count | 70 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, 89bio has paid $3.96 million in taxes.
Income Tax | 3.96M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.66% in the last 52 weeks. The beta is 1.03, so 89bio's price volatility has been similar to the market average.
Beta (1Y) | 1.03 |
52-Week Price Change | -56.66% |
50-Day Moving Average | 9.46 |
200-Day Moving Average | 10.94 |
Relative Strength Index (RSI) | 35.60 |
Average Volume (30 Days) | 1,043,112 |
Short Selling Information
The latest short interest is 10.12 million, so 10.28% of the outstanding shares have been sold short.
Short Interest | 10.12M |
Short Previous Month | 10.75M |
Short % of Shares Out | 10.28% |
Short % of Float | 14.49% |
Short Ratio (days to cover) | 14.36 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -179.96M |
Pretax Income | -161.07M |
Net Income | -165.03M |
EBITDA | -157.09M |
EBIT | -157.49M |
Earnings Per Share (EPS) | -$2.01 |
Balance Sheet
The company has $562.29 million in cash and $27.30 million in debt, giving a net cash position of $534.99 million or $5.44 per share.
Cash & Cash Equivalents | 562.29M |
Total Debt | 27.30M |
Net Cash | 534.99M |
Net Cash Per Share | $5.44 |
Equity / Book Value | 510.54M |
Book Value Per Share | 5.19 |
Working Capital | 536.54M |
Cash Flow
In the last 12 months, operating cash flow was -$138.82 million and capital expenditures -$4,000, giving a free cash flow of -$138.83 million.
Operating Cash Flow | -138.82M |
Capital Expenditures | -4,000 |
Free Cash Flow | -138.83M |
FCF Per Share | -$1.45 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
89bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -80.26% |
Shareholder Yield | -80.26% |
Earnings Yield | -21.23% |
FCF Yield | -17.86% |
Analyst Forecast
The average price target for 89bio is $28.14, which is 256.20% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $28.14 |
Price Target Difference | 256.20% |
Analyst Consensus | Strong Buy |
Analyst Count | 8 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -3.90% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |